Skip to main content

Advertisement

Log in

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To characterize the population pharmacokinetics of bevacizumab and the influence of demographic factors, disease severity, and concomitantly used chemotherapy agents on it’s pharmacokinetic behavior.

Patients and methods

Data from eight clinical trials with bevacizumab administered by intravenous infusion were included. A total of 4,629 bevacizumab concentrations from 491 patients with solid tumors, who received bevacizumab doses ranging from 1 to 20 mg/kg at a dosing frequency ranging from weekly to every 3 weeks, were analyzed using a nonlinear mixed-effects modeling approach (NONMEM).

Results

The best structural model was a two-compartment model with first-order elimination. In the final model, estimated clearance (CL) and central compartment volume of distribution (V c) were 0.207 L/day and 2.39 L for a typical female. The terminal half-life estimate was ∼20 days for both men and women. Body weight and gender were the most significant covariates to explain interpatient variability for CL and V c. Clearance was 26% faster in men than in women. Patients with low serum albumin and high serum alkaline phosphatase had 19 and 23% faster CL, respectively, than a typical patient. Consistent with the long elimination half life, simulations showed that similar steady-state exposures can be maintained when the weekly mg/kg dose rate is maintained, therefore allowing administration of bevacizumab to coincide with the frequency of administration of the cytotoxic agents.

Conclusion

The PK parameters were consistent with those of other IgG molecules. The results support dosing bevacizumab on a once every 2 weeks or once every 3 weeks dosing schedule on a mg/kg basis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Avastin Biological License Application (BLA) (2003) Data on file Genentech, Inc., South San Francisco

  2. AVASTIN (package insert) (2004) Genentech, Inc., South San Francisco, December

  3. Beal SL, Sheiner LB (1992) NONMEM User’s Guide. NONMEM Project Group. University of California, San Francisco

    Google Scholar 

  4. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361–369

    Article  PubMed  CAS  Google Scholar 

  5. Giantonio BJ, Catalano PJ, Meropol NJ et al (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol [ASCO Annual Meeting Proceedings. 23 (no. 16S, Part I of II, June 1 Supplement), 2005:2]

  6. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669076

    Google Scholar 

  7. Gobburu JVS, Lawrence J (2002) Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharmacol Res 19:9–28

    Google Scholar 

  8. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R et al (2002) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850

    Google Scholar 

  9. Hsei VC, Novotny WF, Margolin K et al (2001) Population pharmacokinetic (PK) analysis of bevacizumab (BV) in cancer subjects. Proc Am Soc Clin Oncol 20 (abstract 272)

  10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  11. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191

    Article  PubMed  CAS  Google Scholar 

  12. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65

    Article  PubMed  CAS  Google Scholar 

  13. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668

    Article  PubMed  CAS  Google Scholar 

  14. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G et al (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19:851–856

    PubMed  CAS  Google Scholar 

  15. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  PubMed  CAS  Google Scholar 

  16. Reese D, Frohlich D, Bok R, Corry M, Novotny W, Homgren E, Small E (1999) A Phase II trial of humanized monoclonal antivascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 18:1355a

    Google Scholar 

  17. Sandler AB, Gray R, Brahmer J et al (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol [ASCO Annual Meeting Proceedings, vol 23, no 16S, Part I of II (June 1 Supplement), 2005:4]

  18. Shen BQ et al (2006) Hepatic dysfunction resulting from common bile duct ligation did not affect the pharmacokinetics of bevacizumab (Avastin) in Sprague–Dawley rats. In: Proceedings AACR, vol 47, p 731

  19. Trang JM (1992) Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Ferraiolo BL, Mohler MA, Gloff CA (eds) Protein pharmacokinetics and metabolism. Pharmaceutical biotechnology, vol 1. Plenum Press, New York, pp 223–270

    Google Scholar 

  20. Wahlby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231–252

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Julie Hambleton (Genentech, Inc.) for her review and insightful comments and to the investigators, the clinical research support teams, and to the patients participating in these trials.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bert Lum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, JF., Bruno, R., Eppler, S. et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62, 779–786 (2008). https://doi.org/10.1007/s00280-007-0664-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0664-8

Keywords

Navigation